=DJ BEFORE THE BELL: Medarex, VaxGen Lead Early Gainers NEW YORK (Dow Jones)--Two companies with anthrax products were very popular inpremarket trading Wednesday. The top volume mover was Medarex Inc. (MEDX), whose human antibody against anthrax was shown to be effective in pre-clinical trials conducted on rabbits. Medarex added 18%, or $1.06, to $7.01 in premarket action, according to Island ECN. In a press release Wednesday, the pharmaceutical company said all of the rabbits that received any dose of the antibody survived lethal levels of inhaledanthrax spores, while all rabbits in the control group died within days of their exposure.